Raltegravir, Darunavir/r

PreclinicalSmall molecule

NNational Center for Global Health and Medicine, Japan

Raltegravir, Darunavir/r is one of 10 small molecule programs targeting Tenofovir. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TenofovirCompleted

TenofovirPreclinical

Completed

Competition

Competitive Landscape

9 competitors in Tenofovir

#DrugCompanyPhaseTrials

Tybost

Gilead

Phase 3

6 2

B/F/TAF

Gilead

Phase 3

2 3

ISL/LEN

Gilead

Phase 3

1 4

PTM SEMA

Gilead

Phase 3

1 5

F/TAF

Gilead

Phase 3

1 6

Cobicistat TOS

Gilead

Phase 3

1 7

Third Agent

Gilead

Phase 3

2 8

Lpv/r

Gilead

Phase 3

1 9

Truvada

Gilead

Preclinical

3 10

Raltegravir, Darunavir/r

NNational Center for Global Health and Medicine, Japan

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tenofovir1 trial

Comparing Continuing Tenofovir, Emtricitabine (or Lamivudine) Plus Lopinavir and Switching to Raltegravir Plus Darunavir

Completed·NNational Center for Global Health and Medicine, Japan·N/A·NCT01294761·59 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Raltegravir, Darunavir/r. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Raltegravir, Darunavir/r compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Raltegravir, Darunavir/r. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Center for Global Health and Medicine, Japan company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNational Center for Global Health and Medicine, Japan

Raltegravir, Darunavir/r

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tenofovir1 trial

References

Drug Info

Quick Facts

Related News